Scarica l'app Stockscreener
1.83
6.63%
-0.13
Pre-mercato:
1.84
0.01
+0.55%
Precedente Chiudi:
$1.96
Aprire:
$1.97
Volume 24 ore:
716.30K
Relative Volume:
0.61
Capitalizzazione di mercato:
$57.56M
Reddito:
-
Utile/perdita netta:
$-69.00M
Rapporto P/E:
-0.6583
EPS:
-2.78
Flusso di cassa netto:
$-55.26M
1 W Prestazione:
-4.19%
1M Prestazione:
+12.27%
6M Prestazione:
+19.61%
1 anno Prestazione:
-73.78%
Intervallo 1D:
$1.82
$2.01
Intervallo di 1 settimana:
$1.82
$2.02
Portata 52W:
$1.05
$8.74
Acrivon Therapeutics Inc Stock (ACRV) Company Profile
Nome
Acrivon Therapeutics Inc
Settore
Industria
Telefono
617-207-8979
Indirizzo
480 ARSENAL WAY, SUITE 100, WATERTOWN
Confronta ACRV con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ACRV
Acrivon Therapeutics Inc
|
1.83 | 61.65M | 0 | -69.00M | -55.26M | -2.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Acrivon Therapeutics Inc Stock (ACRV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-05 | Ripresa | Piper Sandler | Overweight |
| 2025-01-31 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2024-09-16 | Aggiornamento | Ladenburg Thalmann | Neutral → Buy |
| 2024-04-29 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2024-03-01 | Iniziato | JMP Securities | Mkt Outperform |
| 2023-12-15 | Ripresa | Jefferies | Buy |
| 2023-10-05 | Iniziato | Maxim Group | Buy |
| 2023-06-02 | Iniziato | Oppenheimer | Outperform |
| 2023-05-08 | Iniziato | BMO Capital Markets | Outperform |
| 2023-04-27 | Iniziato | Ladenburg Thalmann | Buy |
| 2023-04-20 | Iniziato | H.C. Wainwright | Buy |
| 2022-12-12 | Iniziato | Cowen | Outperform |
| 2022-12-12 | Iniziato | Jefferies | Buy |
| 2022-12-12 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Acrivon Therapeutics Inc Borsa (ACRV) Ultime notizie
Is Acrivon Therapeutics Inc. still worth holding after the dipIndex Update & Fast Momentum Entry Tips - newser.com
News impact scoring models applied to Acrivon Therapeutics Inc.July 2025 Trade Ideas & Fast Exit and Entry Strategy Plans - newser.com
How Acrivon Therapeutics Inc. stock valuations compare to rivalsMarket Performance Recap & Daily Technical Stock Forecast Reports - newser.com
What Fibonacci levels say about Acrivon Therapeutics Inc. reboundPortfolio Value Report & Fast Moving Stock Trade Plans - newser.com
Is Acrivon Therapeutics Inc. stock positioned well for digital economyPortfolio Gains Summary & Safe Entry Momentum Stock Tips - newser.com
Acrivon Therapeutics (NASDAQ:ACRV) Given "Sell (E+)" Rating at Weiss Ratings - MarketBeat
Sector ETF performance correlation with Acrivon Therapeutics Inc.July 2025 PreEarnings & Long-Term Investment Growth Plans - newser.com
Acrivon Therapeutics to Host Corporate R&D Event to Provide AP3 Platform Capabilities and Clinical ACR-368 and ACR-2316 Program Updates - 富途牛牛
Risk vs reward if holding onto Acrivon Therapeutics Inc.July 2025 Market Mood & Safe Entry Trade Reports - newser.com
Will Acrivon Therapeutics Inc. stock benefit from sector rotationInflation Watch & Fast Entry Momentum Alerts - newser.com
What to expect from Acrivon Therapeutics Inc. in the next 30 daysJuly 2025 Highlights & High Accuracy Investment Entry Signals - newser.com
Short Interest in Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Rises By 127.8% - Defense World
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Short Interest Up 127.8% in September - MarketBeat
Spotlight On 3 Promising Penny Stocks With Over $50M Market Cap - simplywall.st
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
225,000 Stock Options: Biotech Acrivon Therapeutics Awards Major Inducement Grant to Key New Hire - Stock Titan
Acrivon Therapeutics, Inc. $ACRV Holdings Decreased by Goldman Sachs Group Inc. - Defense World
Brokerages Set Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Target Price at $15.00 - Defense World
Tools to assess Acrivon Therapeutics Inc.’s risk profileTreasury Yields & Stepwise Trade Signal Guides - newser.com
Acrivon Therapeutics Inc Azioni (ACRV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Acrivon Therapeutics Inc Azioni (ACRV) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | 10% Owner |
May 01 '25 |
Sale |
1.34 |
298,886 |
400,507 |
3,104,139 |
| PERCEPTIVE ADVISORS LLC | 10% Owner |
Apr 25 '25 |
Sale |
1.95 |
1,054,669 |
2,056,605 |
4,306,189 |
| PERCEPTIVE ADVISORS LLC | 10% Owner |
Apr 29 '25 |
Sale |
1.41 |
250,000 |
352,500 |
3,840,906 |
| PERCEPTIVE ADVISORS LLC | 10% Owner |
Apr 28 '25 |
Sale |
1.56 |
215,283 |
335,841 |
4,090,906 |
5.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):